1. Home
  2. MLSS vs BCDA Comparison

MLSS vs BCDA Comparison

Compare MLSS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Milestone Scientific Inc.

MLSS

Milestone Scientific Inc.

HOLD

Current Price

$0.35

Market Cap

22.1M

Sector

Health Care

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.19

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLSS
BCDA
Founded
1989
N/A
Country
United States
United States
Employees
N/A
21
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
17.9M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MLSS
BCDA
Price
$0.35
$1.19
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$1.00
$25.00
AVG Volume (30 Days)
189.5K
6.2M
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,973,982.00
N/A
Revenue This Year
$12.64
N/A
Revenue Next Year
$8.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.99
N/A
52 Week Low
$0.22
$0.78
52 Week High
$0.69
$2.45

Technical Indicators

Market Signals
Indicator
MLSS
BCDA
Relative Strength Index (RSI) 50.81 65.01
Support Level $0.29 $1.11
Resistance Level $0.40 $1.34
Average True Range (ATR) 0.03 0.11
MACD -0.00 0.04
Stochastic Oscillator 62.59 87.59

Price Performance

Historical Comparison
MLSS
BCDA

About MLSS Milestone Scientific Inc.

Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: